THE CORPORATE LIBRARY

Related Party Transactions and Outside Related Director Information

Millennium Pharmaceutical, Inc. (MLNM)

3/22/2006 Proxy Information

Mr. Levin served as Chairman of Millennium Pharmaceutical, Inc. from March 1996 to July 2005, Chief Executive Officer from November 1994 to July 2005 and President from 1993 to July 2005.

Dr. Eric S. Lander and Dr. Raju S. Kucherlapati are founders of Millennium Pharmaceutical, Inc.

In November 2003 we entered into a transaction with Portola Pharmaceuticals, Inc., a new biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment and prevention of severe cardiovascular diseases. Charles Homcy, who serves on our Board of Directors, is PortolaÕs President, Chief Executive Officer and a member of PortolaÕs Board of Directors. In connection with this transaction we licensed to Portola certain rights in the area of thrombosis research, sold to Portola certain assets and subleased to Portola a portion of our leased property in South San Francisco. Under the license, we are entitled to receive milestone and royalty payments upon the achievement of certain events. We did not receive any payments under the license during 2005. Under the sublease with us, Portola pays us monthly rent at a rate beginning at approximately $55,000 and increasing to approximately $100,000 over a period of three years, after which the rate will be set at the then-current fair market value for the remainder of the term. During 2005, we received a total of $1,320,852 from Portola under the sublease. Portola also paid us $16,000 per month through the second quarter of 2004 for certain transitional services. As a part of this transaction, we were granted shares of PortolaÕs Series A Preferred Stock valued at $1.0 million. In August 2004 and December 2004 we entered into additional transactions with Portola to license our Factor Xa inhibitor program in return for milestone and royalty payments upon achievement of certain events and to co-develop a device and system for profiling blood deposits based upon a Millennium patent. In December 2005 we amended the 2003 and 2004 license agreements and granted Portola an exclusive license to MillenniumÕs patent for the profiling device and system and certain other rights. As part of these transactions, we received $500,000 in cash and shares of Portola Series B Preferred Stock valued at $500,000. All of these transactions were negotiated on an armÕs-length basis.

3/22/2005 Proxy Information

Dr. Eric S. Lander and Dr. Raju S. Kucherlapati are founders of Millennium Pharmaceutical, Inc.

In November 2003 we entered into a transaction with Portola Pharmaceuticals, Inc., a new biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment and prevention of severe cardiovascular diseases. Charles Homcy, who serves on our Board of Directors, is Portola's President, Chief Executive Officer and a member of Portola's Board of Directors. In connection with this transaction we licensed to Portola certain rights in the areas of thrombosis research, sold to Portola certain assets and subleased to Portola a portion of our leased property in South San Francisco. Under the license, we are entitled to receive milestone and royalty payments upon the achievement of certain events. Under the sublease with us, Portola pays us monthly rent at a rate beginning at approximately $55,000 and increasing to approximately $100,000 over a period of three years, after which the rate will be set at the then-current fair market value for the remainder of the term. Portola also paid us $16,000 per month through the second quarter of 2004 for certain transitional services. As a part of this transaction, we were granted shares of Portola's Series A Preferred Stock valued at $1.0 million. In August 2004 we entered into an additional transaction with Portola to license our Factor Xa inhibitor program in return for milestone and royalty payments upon achievement of certain events. These transactions were negotiated on an arm's-length basis and were reviewed by an independent committee of the Board of Directors.

Millennium has agreements with Dr. Homcy, a former executive officer of Millennium and current member of our Board of Directors, under which he was entitled to certain benefits upon his termination of employment. Dr. Homcy's employment with Millennium terminated on November 7, 2003. Under a Key Employee Change of Control Severance Plan, assumed by Millennium in our merger with COR Therapeutics, Inc., and two letter agreements dated December 24, 2002 and November 7, 2003:

¥ Millennium pays his base salary at the rate he was receiving as of the date of the COR merger ($381,600) for eighteen months after his termination date and paid him $154,700, the pro rata portion of his target bonus for 2003 at the rate set as of the date of the merger (50%);

¥ stock options outstanding as of the date of the COR merger immediately vested and became exercisable as of the date of his termination of employment;

¥ stock options granted to him after our merger with COR that were held by him on his termination date ceased vesting on November 7, 2004, one year from his termination date;

¥ Millennium continued his health benefits for twelve months; and

¥ the payments under these agreements to be received by Dr. Homcy upon termination of employment will be adjusted if necessary to result in the greater amount of payment possible after taking into consideration the excise tax imposed by Section 4999 of the Internal Revenue Code. The Key Employee Change of Control Severance Plan and the letter agreements with Dr. Homcy are filed as exhibits to our Annual Report on Form 10-K that we filed with the Securities and Exchange Commission. Dr. Homcy continues to serve on our Board of Directors.

3/24/2004 Proxy Information

In November 2003 we entered into a transaction with Portola Pharmaceuticals, Inc., a new biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment and prevention of severe cardiovascular diseases. Charles Homcy, who serves on our Board of Directors, is Portola's President, Chief Executive Officer and a member of Portola's Board of Directors. In connection with this transaction we licensed to Portola certain rights in the areas of thrombosis research, sold to Portola certain assets and subleased to Portola a portion of our leased property in South San Francisco. Under the sublease with us, Portola pays us monthly rent at a rate beginning at approximately $55,000 and increasing to approximately $100,000 over a period of three years, after which the rate will be set at the then-current fair market value for the remainder of the term. Portola also pays us $16,000 per month through the second quarter of 2004 for certain transitional services. As a part of this transaction, we were granted shares of Portola's Series A Preferred Stock valued at $1.0 million. This transaction was negotiated on an arm's-length basis and was reviewed by an independent committee of the Board of Directors.

Millennium and Vaughn Kailian, who terminated his employment with Millennium on December 31, 2003, are discussing the possibility of entering into a consulting relationship under which Mr. Kailian would provide consulting services to us.

The Board has also determined that Dr. Kucherlapati and Dr. Lander will no longer be considered independent directors under new NASDAQ stock market listing standards that will become effective as of the date of our 2004 annual meeting of stockholders because they each received consulting fees from Millennium in 2001.

3/18/2003 Proxy Information

Millennium entered into an arrangement with Paul R. Hamelin, a former Millennium Senior Vice President, Commercial Operations, in May 2002. Under the arrangement, Millennium agreed to pay Mr. Hamelin his base salary and continue his medical and dental insurance for seventeen months after his termination date and pay him a pro-rata share of his target 2002 bonus in the amount of $22,500. Under the terms of the arrangement, Millennium forgave the then outstanding principal amount, and corresponding interest, of a loan of $250,000 bearing an interest rate of 5.87% which Millennium made to Mr. Hamelin in January 2001 for the purchase of a home in the Boston area. Under Mr. Hamelin's employment agreement, Millennium had forgiven one-fourth of the loan on December 1, 2001, the one year anniversary of the date of his employment, and was forgiving one-forty eighth of the remaining amount of the loan monthly after that date as long as he remained a Millennium employee. The largest principal balance of the loan outstanding in 2002 was $187,500.